Name: UMIN ID:
Unique ID issued by UMIN | UMIN000008565 |
---|---|
Receipt number | R000010067 |
Scientific Title | Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-road |
Date of disclosure of the study information | 2012/08/01 |
Last modified on | 2018/08/07 21:01:19 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/07/30 14:49:55 | ||
2 | Update | 2013/02/19 18:26:20 | Primary outcomes Key secondary outcomes Key secondary outcomes |
|
3 | Update | 2014/08/30 17:13:40 | TEL TEL Email1 |
|
4 | Update | 2015/08/30 10:18:03 | Recruitment status |
|
5 | Update | 2017/02/02 01:34:57 | Publication of results |
|
6 | Update | 2018/02/14 00:25:58 | Name of primary person or sponsor Organization |
|
7 | Update | 2018/02/14 00:38:47 | Last follow-up date |
|
8 | Update | 2018/08/07 20:59:45 | Recruitment status Date trial data considered complete Date analysis concluded Publication of results |
|
9 | Update | 2018/08/07 21:01:19 | Primary outcomes |